Guide to Pharmaceutical Labelling Excellence

whitePaper | March 10, 2023

This pharma messaging guidebook features 20 proven cognitive science techniques that can be used to optimize pharmaceutical claims and messages.

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.